These are perspectives on GTM for the biotech and pharma industries. As much as these are teaching tips + tricks, I am always learning from you too. Please comment on the entries. And share with others.
Fighting inter-generational kidney disease is my 'why'
Today Endpoints News announced Judo Bio's $100M Series A to create siRNA therapies targeted specifically at kidneys. And I relish reading this as kidney disease is truly my "why" for working passionately for biotech...